{"transactions":[{"id":1130872,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-29T20:01:09.000Z","date":"2025-05-28","kind":"sale","planned":true,"acquired":false,"shares":558,"price":10.07,"value":5619.06,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2806084,"source":{"system":"sec-edgar","filing":"0001140361-25-020754","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020754/form4.xml","form_type":"4"}},{"id":1130871,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-29T20:01:09.000Z","date":"2025-05-27","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.28,"value":20560.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2806642,"source":{"system":"sec-edgar","filing":"0001140361-25-020754","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020754/form4.xml","form_type":"4"}},{"id":1133852,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-27T20:02:13.000Z","date":"2025-05-23","kind":"sale","planned":true,"acquired":false,"shares":182,"price":10.24,"value":1863.68,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2808642,"source":{"system":"sec-edgar","filing":"0001140361-25-020474","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020474/form4.xml","form_type":"4"}},{"id":1133851,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-27T20:02:13.000Z","date":"2025-05-22","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.97,"value":21940.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.215 to $11.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2808824,"source":{"system":"sec-edgar","filing":"0001140361-25-020474","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020474/form4.xml","form_type":"4"}},{"id":1137761,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-22T20:01:08.000Z","date":"2025-05-21","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.83,"value":21660.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.32 to $11.275. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2810824,"source":{"system":"sec-edgar","filing":"0001140361-25-020156","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020156/form4.xml","form_type":"4"}},{"id":1137760,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-22T20:01:08.000Z","date":"2025-05-20","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.25,"value":22500.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.925 to $11.42. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2812824,"source":{"system":"sec-edgar","filing":"0001140361-25-020156","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020156/form4.xml","form_type":"4"}},{"id":1140870,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-20T20:01:17.000Z","date":"2025-05-19","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.11,"value":22220.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.02 to $11.215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2814824,"source":{"system":"sec-edgar","filing":"0001140361-25-019893","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019893/form4.xml","form_type":"4"}},{"id":1140869,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-20T20:01:17.000Z","date":"2025-05-16","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.31,"value":22620.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.82 to $11.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2816824,"source":{"system":"sec-edgar","filing":"0001140361-25-019893","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019893/form4.xml","form_type":"4"}},{"id":1145901,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-16T20:01:12.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.68,"value":21360.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.435 to $10.93. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2818824,"source":{"system":"sec-edgar","filing":"0001140361-25-019468","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019468/form4.xml","form_type":"4"}},{"id":1145900,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-16T20:01:12.000Z","date":"2025-05-14","kind":"sale","planned":true,"acquired":false,"shares":20,"price":11.3,"value":226.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at price of $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2820824,"source":{"system":"sec-edgar","filing":"0001140361-25-019468","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019468/form4.xml","form_type":"4"}},{"id":1149602,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-14T20:04:40.000Z","date":"2025-05-13","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.37,"value":22740.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.16 to $11.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2820844,"source":{"system":"sec-edgar","filing":"0001140361-25-018927","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125018927/form4.xml","form_type":"4"}},{"id":1149601,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-14T20:04:40.000Z","date":"2025-05-12","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.56,"value":21120.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.885. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2822844,"source":{"system":"sec-edgar","filing":"0001140361-25-018927","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125018927/form4.xml","form_type":"4"}},{"id":1192521,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-25T20:01:33.000Z","date":"2025-03-21","kind":"sale","planned":true,"acquired":false,"shares":174,"price":10,"value":1740.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.005. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2824844,"source":{"system":"sec-edgar","filing":"0001140361-25-010234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125010234/form4.xml","form_type":"4"}},{"id":1194912,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-21T20:01:48.000Z","date":"2025-03-20","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.09,"value":20180.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2825018,"source":{"system":"sec-edgar","filing":"0001140361-25-009877","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125009877/form4.xml","form_type":"4"}},{"id":1194911,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-21T20:01:48.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.13,"value":20260.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2827018,"source":{"system":"sec-edgar","filing":"0001140361-25-009877","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125009877/form4.xml","form_type":"4"}},{"id":1197474,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-19T20:01:19.000Z","date":"2025-03-18","kind":"sale","planned":true,"acquired":false,"shares":242,"price":10.24,"value":2478.08,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2829018,"source":{"system":"sec-edgar","filing":"0001140361-25-009424","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125009424/form4.xml","form_type":"4"}},{"id":1197473,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-19T20:01:19.000Z","date":"2025-03-17","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.09,"value":24180.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.795 to $12.38. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2829260,"source":{"system":"sec-edgar","filing":"0001140361-25-009424","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125009424/form4.xml","form_type":"4"}},{"id":1204349,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-17T20:01:39.000Z","date":"2025-03-14","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.31,"value":24620.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.06 to $12.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2831260,"source":{"system":"sec-edgar","filing":"0001140361-25-009017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125009017/form4.xml","form_type":"4"}},{"id":1204348,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-17T20:01:39.000Z","date":"2025-03-13","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.8,"value":23600.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.51 to $11.97. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2833260,"source":{"system":"sec-edgar","filing":"0001140361-25-009017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125009017/form4.xml","form_type":"4"}},{"id":1208172,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-13T20:01:18.000Z","date":"2025-03-12","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.74,"value":23480.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $12.135. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2835260,"source":{"system":"sec-edgar","filing":"0001140361-25-008623","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125008623/form4.xml","form_type":"4"}},{"id":1208171,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-13T20:01:18.000Z","date":"2025-03-11","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.4,"value":22800.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.92 to $11.845. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2837260,"source":{"system":"sec-edgar","filing":"0001140361-25-008623","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125008623/form4.xml","form_type":"4"}},{"id":1212999,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-11T20:01:45.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.14,"value":20280.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2839260,"source":{"system":"sec-edgar","filing":"0001140361-25-008091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125008091/form4.xml","form_type":"4"}},{"id":1212998,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-11T20:01:45.000Z","date":"2025-03-07","kind":"sale","planned":true,"acquired":false,"shares":1906,"price":10.13,"value":19307.78,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.365. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2841260,"source":{"system":"sec-edgar","filing":"0001140361-25-008091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125008091/form4.xml","form_type":"4"}},{"id":1212997,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-11T20:01:45.000Z","date":"2025-03-07","kind":"sale","planned":true,"acquired":false,"shares":41,"price":12.14,"value":497.74,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2843166,"source":{"system":"sec-edgar","filing":"0001140361-25-008091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125008091/form4.xml","form_type":"4"}},{"id":1212996,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-11T20:01:45.000Z","date":"2025-03-07","kind":"sale","planned":true,"acquired":false,"shares":53,"price":13.03,"value":690.59,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.80 to $13.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2843207,"source":{"system":"sec-edgar","filing":"0001140361-25-008091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125008091/form4.xml","form_type":"4"}},{"id":1218000,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-07T21:02:06.000Z","date":"2025-03-06","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.8,"value":21600.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.63 to $11.17. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2843260,"source":{"system":"sec-edgar","filing":"0001140361-25-007602","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125007602/form4.xml","form_type":"4"}},{"id":1217999,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-07T21:02:06.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.98,"value":21960.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.63 to $11.23. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2845260,"source":{"system":"sec-edgar","filing":"0001140361-25-007602","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125007602/form4.xml","form_type":"4"}},{"id":1223519,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-05T21:01:55.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.86,"value":21720.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.03. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2847260,"source":{"system":"sec-edgar","filing":"0001140361-25-007173","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125007173/form4.xml","form_type":"4"}},{"id":1223518,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-05T21:01:55.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.23,"value":22460.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.95 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2849260,"source":{"system":"sec-edgar","filing":"0001140361-25-007173","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125007173/form4.xml","form_type":"4"}},{"id":1236551,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-03T21:01:24.000Z","date":"2025-02-28","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.41,"value":22820.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2851260,"source":{"system":"sec-edgar","filing":"0001140361-25-006738","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125006738/form4.xml","form_type":"4"}},{"id":1236550,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-03-03T21:01:24.000Z","date":"2025-02-27","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.33,"value":22660.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.18 to $11.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2853260,"source":{"system":"sec-edgar","filing":"0001140361-25-006738","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125006738/form4.xml","form_type":"4"}},{"id":1241346,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-27T21:02:02.000Z","date":"2025-02-26","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.63,"value":23260.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $11.86. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2855260,"source":{"system":"sec-edgar","filing":"0001140361-25-006273","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125006273/form4.xml","form_type":"4"}},{"id":1241345,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-27T21:02:02.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.37,"value":22740.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.20 to $11.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2857260,"source":{"system":"sec-edgar","filing":"0001140361-25-006273","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125006273/form4.xml","form_type":"4"}},{"id":1247093,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-25T21:01:23.000Z","date":"2025-02-24","kind":"sale","planned":true,"acquired":false,"shares":187,"price":11.52,"value":2154.24,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.43 to $11.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2859260,"source":{"system":"sec-edgar","filing":"0001140361-25-005842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005842/form4.xml","form_type":"4"}},{"id":1247092,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-25T21:01:23.000Z","date":"2025-02-24","kind":"sale","planned":true,"acquired":false,"shares":1813,"price":10.6,"value":19217.8,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.41 to $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2859447,"source":{"system":"sec-edgar","filing":"0001140361-25-005842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005842/form4.xml","form_type":"4"}},{"id":1247091,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-25T21:01:23.000Z","date":"2025-02-21","kind":"sale","planned":true,"acquired":false,"shares":182,"price":12.6,"value":2293.2,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.71. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2861260,"source":{"system":"sec-edgar","filing":"0001140361-25-005842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005842/form4.xml","form_type":"4"}},{"id":1247090,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-25T21:01:23.000Z","date":"2025-02-21","kind":"sale","planned":true,"acquired":false,"shares":1818,"price":11.84,"value":21525.12,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.54 to $12.53. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2861442,"source":{"system":"sec-edgar","filing":"0001140361-25-005842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005842/form4.xml","form_type":"4"}},{"id":1253610,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-21T21:01:11.000Z","date":"2025-02-20","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.4,"value":24800.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.15 to $12.61. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2863260,"source":{"system":"sec-edgar","filing":"0001140361-25-005420","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005420/form4.xml","form_type":"4"}},{"id":1253609,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-21T21:01:11.000Z","date":"2025-02-19","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.29,"value":24580.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.1 to $12.62. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2865260,"source":{"system":"sec-edgar","filing":"0001140361-25-005420","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005420/form4.xml","form_type":"4"}},{"id":1261063,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-19T21:01:19.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.49,"value":24980.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.26 to $12.78. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2867260,"source":{"system":"sec-edgar","filing":"0001140361-25-005113","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005113/form4.xml","form_type":"4"}},{"id":1261062,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-19T21:01:19.000Z","date":"2025-02-14","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.94,"value":23880.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.78 to $12.05. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2869260,"source":{"system":"sec-edgar","filing":"0001140361-25-005113","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125005113/form4.xml","form_type":"4"}},{"id":1267925,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-14T21:00:40.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.69,"value":23380.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.59 to $11.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2871260,"source":{"system":"sec-edgar","filing":"0001140361-25-004744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125004744/form4.xml","form_type":"4"}},{"id":1267924,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-14T21:00:40.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.49,"value":22980.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.645. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2873260,"source":{"system":"sec-edgar","filing":"0001140361-25-004744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125004744/form4.xml","form_type":"4"}},{"id":1272180,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-13T01:45:55.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":1878,"price":11.52,"value":21634.56,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.45 to $11.61. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2875260,"source":{"system":"sec-edgar","filing":"0001140361-25-004126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125004126/form4.xml","form_type":"4"}},{"id":1272179,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-13T01:45:55.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.9,"value":23800.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.72 to $12.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2877138,"source":{"system":"sec-edgar","filing":"0001140361-25-004126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125004126/form4.xml","form_type":"4"}},{"id":1274461,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-11T21:01:26.000Z","date":"2025-02-07","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.16,"value":24320.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.01 to $12.475. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2879158,"source":{"system":"sec-edgar","filing":"0001140361-25-003831","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125003831/form4.xml","form_type":"4"}},{"id":1274460,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-11T21:01:26.000Z","date":"2025-02-06","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.85,"value":25700.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.70 to $13.05. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2881138,"source":{"system":"sec-edgar","filing":"0001140361-25-003831","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125003831/form4.xml","form_type":"4"}},{"id":1280576,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-06T21:01:22.000Z","date":"2025-02-05","kind":"sale","planned":true,"acquired":false,"shares":20,"price":12.84,"value":256.8,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.835 to $12.84. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2883138,"source":{"system":"sec-edgar","filing":"0001140361-25-003426","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125003426/form4.xml","form_type":"4"}},{"id":1280575,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-06T21:01:22.000Z","date":"2025-02-05","kind":"sale","planned":true,"acquired":false,"shares":1980,"price":12.39,"value":24532.2,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.82 to $12.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2883158,"source":{"system":"sec-edgar","filing":"0001140361-25-003426","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125003426/form4.xml","form_type":"4"}},{"id":1280574,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-06T21:01:22.000Z","date":"2025-02-04","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.62,"value":23240.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.33 to $11.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2885138,"source":{"system":"sec-edgar","filing":"0001140361-25-003426","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125003426/form4.xml","form_type":"4"}},{"id":1285469,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-04T21:01:11.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.47,"value":22940.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.26 to $11.66. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2887138,"source":{"system":"sec-edgar","filing":"0001140361-25-002995","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002995/form4.xml","form_type":"4"}},{"id":1285468,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-02-04T21:01:11.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.51,"value":23020.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.36 to $11.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2889138,"source":{"system":"sec-edgar","filing":"0001140361-25-002995","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002995/form4.xml","form_type":"4"}},{"id":1289826,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-31T21:01:15.000Z","date":"2025-01-30","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.37,"value":22740.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.15 to $11.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2891138,"source":{"system":"sec-edgar","filing":"0001140361-25-002702","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002702/form4.xml","form_type":"4"}},{"id":1289825,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-31T21:01:15.000Z","date":"2025-01-29","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.43,"value":22860.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.28 to $11.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2893138,"source":{"system":"sec-edgar","filing":"0001140361-25-002702","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002702/form4.xml","form_type":"4"}},{"id":1292082,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-29T21:01:30.000Z","date":"2025-01-28","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.51,"value":23020.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.78. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2895138,"source":{"system":"sec-edgar","filing":"0001140361-25-002340","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002340/form4.xml","form_type":"4"}},{"id":1292081,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-29T21:01:30.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.18,"value":22360.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.01 to $11.37. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2897138,"source":{"system":"sec-edgar","filing":"0001140361-25-002340","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002340/form4.xml","form_type":"4"}},{"id":1294700,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-27T21:01:23.000Z","date":"2025-01-24","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.89,"value":21780.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.51 to $11.21. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2899138,"source":{"system":"sec-edgar","filing":"0001140361-25-002062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002062/form4.xml","form_type":"4"}},{"id":1294699,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-27T21:01:23.000Z","date":"2025-01-23","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.49,"value":20980.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.42 to $10.74. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2901138,"source":{"system":"sec-edgar","filing":"0001140361-25-002062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125002062/form4.xml","form_type":"4"}},{"id":1295808,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-24T21:01:57.000Z","date":"2025-01-22","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.63,"value":21260.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.79. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2903138,"source":{"system":"sec-edgar","filing":"0001140361-25-001891","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001891/form4.xml","form_type":"4"}},{"id":1295807,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-24T21:01:57.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.85,"value":21700.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.35. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2905138,"source":{"system":"sec-edgar","filing":"0001140361-25-001891","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001891/form4.xml","form_type":"4"}},{"id":1298961,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-21T21:01:28.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.72,"value":21440.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.93. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2907138,"source":{"system":"sec-edgar","filing":"0001140361-25-001526","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001526/form4.xml","form_type":"4"}},{"id":1298960,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-21T21:01:28.000Z","date":"2025-01-16","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.71,"value":21420.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $10.91. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2909138,"source":{"system":"sec-edgar","filing":"0001140361-25-001526","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001526/form4.xml","form_type":"4"}},{"id":1301676,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-16T21:01:17.000Z","date":"2025-01-15","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.85,"value":21700.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.74 to $11.08. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2911138,"source":{"system":"sec-edgar","filing":"0001140361-25-001283","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001283/form4.xml","form_type":"4"}},{"id":1301675,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-16T21:01:17.000Z","date":"2025-01-14","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.39,"value":20780.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.13 to $10.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2913138,"source":{"system":"sec-edgar","filing":"0001140361-25-001283","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001283/form4.xml","form_type":"4"}},{"id":1303738,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-14T21:01:15.000Z","date":"2025-01-13","kind":"sale","planned":true,"acquired":false,"shares":56,"price":10.1,"value":565.6,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2915138,"source":{"system":"sec-edgar","filing":"0001140361-25-001059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001059/form4.xml","form_type":"4"}},{"id":1303737,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-14T21:01:15.000Z","date":"2025-01-10","kind":"sale","planned":true,"acquired":false,"shares":1057,"price":10.02,"value":10591.14,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.38. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2915194,"source":{"system":"sec-edgar","filing":"0001140361-25-001059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125001059/form4.xml","form_type":"4"}},{"id":1305585,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-10T21:01:48.000Z","date":"2025-01-03","kind":"sale","planned":true,"acquired":false,"shares":833,"price":11.85,"value":9871.05,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This Form 4 amends the Form 4 filed on January 6, 2025 to reflect the correct transaction date as of January 3, 2025. The original filing incorrectly reported the transaction date as of January 3, 2024."}],"balance_after":2918467,"source":{"system":"sec-edgar","filing":"0001140361-25-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000827/form4.xml","form_type":"4/A","original_submission_date":"2025-01-06"}},{"id":1307052,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-08T21:01:18.000Z","date":"2025-01-07","kind":"sale","planned":true,"acquired":false,"shares":1275,"price":10.02,"value":12775.5,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.24. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2916251,"source":{"system":"sec-edgar","filing":"0001140361-25-000610","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000610/form4.xml","form_type":"4"}},{"id":1307051,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-08T21:01:18.000Z","date":"2025-01-06","kind":"sale","planned":true,"acquired":false,"shares":941,"price":10.16,"value":9560.56,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2917526,"source":{"system":"sec-edgar","filing":"0001140361-25-000610","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000610/form4.xml","form_type":"4"}},{"id":1311459,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-06T21:01:47.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":833,"price":11.85,"value":9871.05,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.73 to $12.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2918467,"source":{"system":"sec-edgar","filing":"0001140361-25-000339","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000339/form4.xml","form_type":"4"}},{"id":1311458,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-06T21:01:47.000Z","date":"2025-01-03","kind":"sale","planned":true,"acquired":false,"shares":1167,"price":11.03,"value":12872.01,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.73 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2919300,"source":{"system":"sec-edgar","filing":"0001140361-25-000339","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000339/form4.xml","form_type":"4"}},{"id":1311457,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-06T21:01:47.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.4,"value":24800.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.99 to $12.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2920467,"source":{"system":"sec-edgar","filing":"0001140361-25-000339","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000339/form4.xml","form_type":"4"}},{"id":1318915,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-02T21:06:27.000Z","date":"2024-12-31","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.3,"value":24600.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.01 to $12.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2922467,"source":{"system":"sec-edgar","filing":"0001140361-25-000074","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000074/form4.xml","form_type":"4"}},{"id":1318914,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-01-02T21:06:27.000Z","date":"2024-12-30","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.5,"value":25000.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.07 to $12.75. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2924467,"source":{"system":"sec-edgar","filing":"0001140361-25-000074","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000074/form4.xml","form_type":"4"}},{"id":1320550,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-30T21:01:14.000Z","date":"2024-12-27","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":12.58,"value":25160.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.40 to $13.14. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2926467,"source":{"system":"sec-edgar","filing":"0001140361-24-050588","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050588/form4.xml","form_type":"4"}},{"id":1320549,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-30T21:01:14.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":356,"price":13.05,"value":4645.8,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.13. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2928467,"source":{"system":"sec-edgar","filing":"0001140361-24-050588","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050588/form4.xml","form_type":"4"}},{"id":1320548,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-30T21:01:14.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":1644,"price":12.62,"value":20747.28,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.97. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2928823,"source":{"system":"sec-edgar","filing":"0001140361-24-050588","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050588/form4.xml","form_type":"4"}},{"id":1322086,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-26T21:01:20.000Z","date":"2024-12-24","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.93,"value":23860.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.76 to $12.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2930467,"source":{"system":"sec-edgar","filing":"0001140361-24-050413","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050413/form4.xml","form_type":"4"}},{"id":1322085,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-26T21:01:20.000Z","date":"2024-12-23","kind":"sale","planned":true,"acquired":false,"shares":296,"price":12.44,"value":3682.24,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.41 to $12.48. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2932467,"source":{"system":"sec-edgar","filing":"0001140361-24-050413","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050413/form4.xml","form_type":"4"}},{"id":1322084,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-26T21:01:20.000Z","date":"2024-12-23","kind":"sale","planned":true,"acquired":false,"shares":1704,"price":12.24,"value":20856.96,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $12.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2932763,"source":{"system":"sec-edgar","filing":"0001140361-24-050413","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050413/form4.xml","form_type":"4"}},{"id":1323182,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-23T21:01:45.000Z","date":"2024-12-20","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.9,"value":21800.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.11. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2934467,"source":{"system":"sec-edgar","filing":"0001140361-24-050250","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050250/form4.xml","form_type":"4"}},{"id":1323181,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-23T21:01:45.000Z","date":"2024-12-19","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.82,"value":21640.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.61 to $11.35. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2936467,"source":{"system":"sec-edgar","filing":"0001140361-24-050250","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124050250/form4.xml","form_type":"4"}},{"id":1325685,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-19T21:01:39.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":429,"price":12.11,"value":5195.19,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.70 to $12.46. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2938467,"source":{"system":"sec-edgar","filing":"0001140361-24-049939","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124049939/form4.xml","form_type":"4"}},{"id":1325684,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-19T21:01:39.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":1571,"price":11.17,"value":17548.07,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.70 to $11.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2938896,"source":{"system":"sec-edgar","filing":"0001140361-24-049939","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124049939/form4.xml","form_type":"4"}},{"id":1325683,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-19T21:01:39.000Z","date":"2024-12-17","kind":"sale","planned":true,"acquired":false,"shares":788,"price":11.23,"value":8849.24,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.10 to $11.37. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2940467,"source":{"system":"sec-edgar","filing":"0001140361-24-049939","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124049939/form4.xml","form_type":"4"}},{"id":1325682,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-12-19T21:01:39.000Z","date":"2024-12-17","kind":"sale","planned":true,"acquired":false,"shares":1212,"price":10.94,"value":13259.28,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.10 to $11.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2941255,"source":{"system":"sec-edgar","filing":"0001140361-24-049939","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124049939/form4.xml","form_type":"4"}},{"id":1431653,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-17T01:01:34.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":9.98,"expiration_date":"2034-08-14","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001140361-24-037709","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124037709/form4.xml","form_type":"4"}},{"id":1731642,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-23T00:40:34.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":4510047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China (\"Beijing Continent\"), terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China (\"Beijing Continent\"), terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China (\"Beijing Continent\"), terminated its 2021 Stock Incentive Plan (the \"2021 Plan\") and each option (a \"BC Option\") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan."}],"balance_after":4510047,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":4510047},"source":{"system":"sec-edgar","filing":"0001140361-23-054518","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123054518/form4.xml","form_type":"4"}}]}